Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma

Chao Li1,2†, Xiaobin Zheng3†, Pansong Li4, Huijuan Wang5, Jie Hu6, Lin Wu7, Zhijie Wang8, Hui Guo9, Fang Wu10, Wenzhao Zhong11, Chengzhi Zhou12, Qian Chu13, Jun Zhao14, Xinlong Zheng3, Weijin Xiao1,2, Weifeng Zhu1,2, Longfeng Zhang3, Qian Li4, Kan Jiang3, Qian Miao3, Biao Wu3, Yiquan Xu5, Shiwen Wu5, Haibo Wang3, Shanshan Yang3, Yujing Li3, Xuefeng Xia4, Xin Yi4, Cheng Huang3, Bo Zhu15,16* and Gen Lin3*

1Department of Pathology, College of Clinical Medicine for Oncology, Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, 2Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China, 3Department of Thoracic Oncology, College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou Cancer Hospital, Fuzhou, China, 4Geneplus-Beijing Institute, Beijing, China, 5Henan Cancer Hospital/ Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, 6Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China, 7Department of Thoracic Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China, 8State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 9Department of Medical Oncology, The First Affiliated Hospital of Xian Jiaotong University, Xian, China, 10Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China, 11Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, 12The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, China, 13Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 14Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital and Institute, Beijing, China, 15Chongqing Key Laboratory of Immunotherapy, Chongqing, China, 16Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China

Lung adenosquamous carcinoma (ASC) is an uncommon histological subtype. We aimed to characterize the tumor immune microenvironment (TIME) in lung ASC and estimate patient response to immune checkpoint inhibitors (ICIs), which have never been systematically investigated. In cohort I, we collected 30 ASCs from a single center for analysis of TIME characteristics, including immuno-phenotyping, tumor mutation burden (TMB), T-cell receptor (TCR) repertoires, tumor-infiltrating lymphocytes (TILs), and immune checkpoint expression. Twenty-two (73.3%) patients were EGFR-positive. The TIME was defined by immune-excluded (60%) and immune-desert phenotype (40%). Strikingly, programmed cell death-ligand 1 (PD-L1) and programmed cell
death-1 (PD-1) were predominantly expressed in squamous cell carcinoma components (SCCCs) versus adenocarcinoma components (ACCs), where enhanced CD4+ FOXP3+ regulatory T cell and attenuated CD57+ natural killer cell infiltration were present, consistent with a landscape of fewer innate immune cells, more immunosuppressive cells. SCCCs had higher TMB, higher TCR clonality, and lower TCR diversity than ACC. In cohort III, the efficacy of ICI-based therapy was estimated using a real-world data of 46 ASCs from 11 centers. Majority of 46 patients were driver genes negative and unknown mutation status, 18 (39%) and 18 (39%), respectively. The overall objective response rate of 28%, median progression-free survival of 6.0 months (95% confidence interval [CI] 4.3–7.7), and median overall survival of 24.7 months (95% CI 7.2–42.2) were observed in the ICI-based treatment. This work ascertains suppressive TIME in lung ASC and genetic and immune-heterogeneity between ACCs and SCCCs. Lung ASC patients have a moderate response to ICI-based immunotherapy.

KEYWORDS
lung adenosquamous carcinoma, tumor immune microenvironment, heterogeneity, PD-L1 expression, immune checkpoint inhibitor

Introduction

Lung adenosquamous carcinoma (ASC) is an uncommon histological subtype, accounting for 0.4% to 4% of lung cancers (1, 2). Pathologically, ASC consists of adenocarcinoma components (ACCs) and squamous cell carcinoma components (SCCCs), according to the World Health Organization (WHO) histologic classification of lung cancers (3). Due to the absence of specific management for lung ASC, current options are confined to those listed in non-small cell lung cancer (NSCLC) guidelines. However, it is pathologically heterogeneous and thereby widely accepted as an NSCLC subtype more difficult to treat than classical lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), often associated with a worse prognosis (4–6).

Recently, ACCs and SCCCs of ASC have been proven to stem from a monoclonal cell ancestor and evolve into two subtypes. A plausible theory for the monoclonal origin of ASC that receives from the evidence of shared driver genes in ACC and SCCC, such as mutated EGFR and (Kirsten ras) KRAS genes, has been more appreciated (7–10). Our recent study of genomic profiling of paired ACCs and SCCCs using a 1,021-gene panel has provided another piece of substantial evidence to support the theory (11). Specifically, the two types of pathological components have trunk alterations in the phylogenetic tree, EGFR, TP53, ERBB2, PIK3CA mutations, and EGFR copy number gain and MDM2 copy number loss in the trunk. The high frequency of EGFR mutations and similarity between genomic landscapes of lung ASC trunk mutations and pure LUAD indicate that lung ASC may originate from a subset of glandular cancer cells. ACCs and SCCCs are genetically heterogeneous due to universal branch evolution. ASC patients harboring EGFR mutations may benefit from EGFR tyrosine kinase inhibitors (EGFR-TKIs). All these studies have offered improved insight into ASC origin for better treatment options.

Immune checkpoint inhibitor (ICI)–based therapies targeting CTLA4 or PD1/PD-L1 have achieved impressive success in the treatment of lung cancer over the last decade. Mechanisms of how the complex tumor immune microenvironment (TIME) determines response to ICI therapies have been highlighted (12). However, whether lung ASC patients can benefit from immunotherapy remains uncertain due to the scarce knowledge or clinical data on the TIME of the rare subtype. Shi et al. reported comparable PD-L1 expression between lung ACCs and LUAD (11.1% and 13.5%), lung SCCCs and LUSC (38.89% and 28.9%) (13). That means anti-PD1/L1 agents can be effective for certain lung ASC cases. Thus, a more comprehensive understanding of ASC TIME for the development of disease management is needed.

In this study, our objectives are twofolded: to characterize the heterogeneity of the TIME within lung ASC and estimate patient response to ICIs. We retrospectively analyzed the genetic and clinicopathological data from lung ASC patients for assessments of immunophenotype, lymphocyte infiltration
pattern, immune checkpoint expression, tumor mutation burden (TMB), and T-cell receptor (TCR) repertoire and the estimation of immunotherapy efficacy. This work will offer a fundamental understanding of TIME patterns closely associated with ICI-based treatments for lung ASC.

Methods

Patients and samples

Three independent cohorts of patients were enrolled. Cohort I, for assessment of immune parameters, contained 30 primary tumor samples from consecutive patients who underwent complete resection at Fujian Cancer Hospital between June 2011 and December 2018 but did not receive any anticancer treatment prior to surgery. Two board-certified pathologists independently reviewed all samples and performed immunohistochemistry (IHC). IHC biomarkers including TTF-1, Napsin A, p40, and CK5/6 were utilized to identify and distinguish ACCs and SCCCs (11). Cohort II of 60 LUAD and LUSC from Geneplus-Beijing (https://www.geneplus.org.cn/) were selected for TMB and TCR comparisons. In Cohort III, 46 lung ASC patients with complete efficacy and survival data from 11 cancer centers were included for estimation of immunotherapy efficacy based on the following conditions: (1) patients who were diagnosed with stage IV lung ASC or suffered a relapse after surgery; (2) and treated with anti-PD-1/PD-L1 agents (single or combined with chemotherapy) for at least one cycle, (3) and received efficacy evaluation per RECIST v1.1 criterion at least once after the first dose (baseline).

Microdissection of tumor samples

IHC biomarkers, namely, TTF-1, NapsinA, p40, and CK5/6 were used to distinguish and identify ACCs and SCCCs. Manual microdissection was carried out in the area where the ACCs and SCCCs are clearly separated. Laser-capture microdissection was carried out on selective samples that contained both histologic components that are not separable by normal manual microdissection.

Immune cell phenotyping

Immune cell phenotyping was performed based on the density and localization of lymphocytes, as previously described (14). Briefly, the density and localization of lymphocytes were determined on hematoxylin and eosin (H&E) stained sections per recommendations in the International TILs Working Group 2014 (15). The tumor-infiltrating lymphocyte (TIL) landscape of all mononuclear cells from patients was assessed in the stromal compartment within the borders of an invasive lesion at five random fields in each section at ×200 magnification. The proportion of each TIL subpopulation was calculated based on the percentage of the area occupied by mononuclear cells over the stromal area both around the tumor border and inside the tumor mass. The mean TIL percentage of each sample was recorded. Patients were classified into three groups: (1) immune-inflamed phenotype, depending on the lymphocyte density detected inside the tumor mass in proximity to tumor cells was ≥ 10%, regardless of lymphocyte status in the stromal area around the tumor border; (2) immune-excluded, with the lymphocyte density in the stromal area around the tumor border of ≥10% and a negligible (<10%) amount of lymphocytes inside the tumor mass; (3) immune-desert phenotype, wherein the lymphocyte density was negligible (<10%) in both the tumor mass and the stromal area.

Next-generation sequencing and tumor mutation burden estimation

DNA and sequencing libraries were prepared using a sequencing panel of 1,021 cancer-related genes, as described in our previous report (11). Libraries were sequenced to a uniform median coverage of 515×. Somatic mutations with a variant allele fraction (VAF) ≥2% and at least five high-quality reads (a Phred score ≥30, mapping quality ≥30, and without paired-end read bias) were identified. TMB was defined as the number of all nonsynonymous mutations per 0.7 Mb of targeted coding regions.

T-cell receptor sequencing

FFPE DNA was amplified in a bias-controlled multiplex polymerase chain reaction (PCR) system. Then, we performed human TCRβ chain complementarity-determining region 3 (CDR3) profiling through high-throughput sequencing on the IR-seq platform (Geneplus-Beijing, Beijing, China) (16). CDR3 sequences were identified and assigned using the MiXCR software package (17). TCRβ CDR3 diversity of lung ASC tissues was calculated based on the Shannon entropy index, which is a function of both the relative number of clonotypes present and the relative abundance or distribution of each clonotype (16). TCR clonality was employed to assess the clonal expansion of tumor-specific T cells and defined as 1– (Shannon entropy index)/ln(number of productive unique sequences) (18).
Multiple immunofluorescences staining

Multiple immunofluorescences (MIFs) staining was performed on sections (4-mm thickness) from FFPE human lung ASC samples derived from cohort 1 patients. All slides were deparaffinized manually using xylene, rehydrated in a graded ethanol series, and washed in tap water before microwave treatment (MWT) for heat-induced epitope retrieval in tris-EDTA buffer (pH 9; 643901; Klinipath, Duiven, the Netherlands). Endogenous peroxidase was blocked with Antibody Diluent/Block (72424205; PerkinElmer, Massachusetts, USA). Protein blocking was performed using Antibody Diluent/Block. One antigen requires one round of labeling, including primary antibody incubation, secondary antibody incubation, and tyramide signal amplification (TSA) visualization, followed by labeling of the next antibody.

Two panels were used to perform multiple immunofluorescence (MIF) staining, CD3 (ZM0417, Zsbio Beijing, China), CD4 (ZM0418, Zsbio Beijing, China), FOXP3 (ab20034, Abcam Cambridge, UK), TIM3 (CST45208S, Cell Signaling Technology Massachusetts, USA), and LAG3 (ab40468, Abcam Cambridge, UK) were tested in panel 1, whereas CD8 (ZA0508, Zhibo Beijing, China), CD57 (ZM0058, Zhibo Beijing, China), CD68 (ZM0060, Zhibo Beijing, China), CD163 (ZM0428, Zhibo Beijing, China), PD1 (ZM0381, Zhibo Beijing, China), and PD-L1 (ZA0629, Zhibo Beijing, China) in panel 2. Primary antibodies CD3, CD57, CD68, PD-1, PD-L1, LAG3, TIM3, and FOXP3 were applied on slides for 1-h incubation at 37°C, and anti-CD4, CD8, and CD163 antibodies were employed for overnight incubation at 4°C, followed incubation with Opal Polymer HRP Ms+Rb (2414515; PerkinElmer, Massachusetts, USA), containing fluorophores 4,6-diamidino-2-phenylindole (DAPI), Opal 520 (CD3), Opal 570 (CD4), Opal 620 (LAG3), Opal 650 (TIM3), Opal 690 (FOX-P3), Opal 620 (CD57), Opal 520 (CD68), Opal 570 (PD-L1), Opal 540 (CD80), Opal 650 (PD1), Opal 690 (CD163), and TSA Coumarin system (NEL703001KT; PerkinElmer, Massachusetts, USA). MWT was performed with tris-EDTA buffer (pH 9) to remove antibody-TSA complexes. TSA single-stained slides were made with MWT, counterstained with DAPI for 5 min, and mounted with Antifade Mounting Medium (I0052; NobleRyder, Beijing, China).

Tissue imaging and MIF data analysis

Slides were scanned for electronic review using the PerkinElmer Vectra (Vectra 3.0.5; PerkinElmer, Massachusetts, USA). Multispectral images were unmixed using spectral libraries built from images of the library stains for each fluorophore using the inForm Advanced Image Analysis software (inForm 2.3.0; PerkinElmer, Massachusetts, USA). A selection of five to 10 representative original multispectral images was utilized for training of the inForm Tissue Finder to learn tissue and cell segmentation, identify phenotypes, and estimate positivity scores. All the settings applied to the training images were saved within an algorithm to allow a batch analysis of multiple original multispectral images of the same sample (19). TIL infiltration pattern and type in tumorous, stromal, and total regions (the sum of tumorous and stromal areas) was investigated.

PD-L1 immunohistochemistry

PD-L1 expression was verified using the Dako PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Santa Clara, CA, USA). The tumor proportion score (TPS) of PD-L1 was recorded as the percentage of at least 100 viable tumor cells exhibiting complete or partial PD-L1 membrane staining (20). Pathologists from a certified commercial vendor provided TPS interpretations.

Efficacy and outcome measures

The best response of complete response (CR), partial response (PR), stable disease (SD), and progressed disease (PD) after immunotherapy (single or combined with chemotherapy) were recorded. Objective response rate (ORR) and disease control rate (DCR) were calculated. ORR was defined as the proportion of patients achieving CR and PR, and DCR the proportion of those achieving CR, PR, and SD. Progression-free survival (PFS) was recorded from initiation of treatment with immunotherapy until disease progression, death from any cause, or the last follow-up visit. Overall survival (OS) was measured from treatment initiation to death.

Statistical analysis

All data were analyzed using R Package (Version 3.3.0) or Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The Mann–Whitney test was applied for unpaired observations and Wilcoxon matched-pairs signed-rank test for paired data. Spearman correlation was applied to assess the correlation of TMB with immune checkpoint expression, TIL infiltration, and TCR diversity. PFS and OS were illustrated using the Kaplan–Meier method. A two-sided p < 0.05 was considered statistically significant.
Results

Lung adenosquamous carcinoma shows immune-excluded and immune-desert immunophenotype

Thirty patients in cohort I were recruited for immunophenotyping. Patient characteristics were summarized in Figure 1A. Pathologically, ACC-predominant, SCCC-predominant, and ACC-SCCC-balanced samples accounted for 33% (n = 10), 50% (n = 15), and 17% (n = 5). Mutationally, EGFR mutation status was tested in 28 patients, 22 of whom were EGFR-mutant (Figure 1A).

Immunophenotyping data of lung ASCs were analyzed by reviewing both ACC and SCC regions on pathological images (Figure 1A). The results showed that immune-excluded and immune-desert phenotypes accounted for 60% and 40% of all ASCs, respectively. No immune-inflamed phenotype was found. Of lung ACC samples, 77% (23 out of 30) were immune-excluded, and the remanent immune-desert phenotype; 47% of SCCCs displayed immune-excluded versus 53% immune-desert. No immune-inflamed phenotype was found in either ACCs or SCCCs. About half of the patients had the same phenotype in ACCs and SCCCs, and the others unanimously showed immune-desert phenotype in SCCCs and immune-excluded in matched ACCs. Classical immunophenotypes were showed in Figures 1B–D.

Predominant expression of PD-L1 in squamous cell carcinoma components versus adenocarcinoma components

Expressions of four immune checkpoints, PD-1, PD-L1, TIM3, and LAG3, were quantified in paired ACCs and SCCs using MIF assay (Figure 2). The density of positive cells was calculated in tumorous, stromal, and total regions (containing the tumor and stroma regions). Pronounced expression heterogeneity of PD-L1 or PD-1 expression was detectable.
between SCCC and ACC in the three regions. SCCC illustrated strong and extensive PD-L1 expression (median proportion 8.5% vs. 1.2%, \( p < 0.001 \)) and elevated PD-1 (4.7% vs. 1.5%, \( p = 0.0046 \)) in the total region compared with ACCs (Figure 2A). One case of classic ASC showed PD-L1 and PD-1 expressions in SCCC and ACCs (Figure 2B). Similar results were observed in tumorous and stromal regions (Supplementary Figures 1A, B). The PD-L1 expression pattern was further supported by 22C3-based anti-PD-L1 antibody IHC (Figure 2C). Higher PD-L1/PD-1 expression was positively correlated with ACC and SCCC areas (Supplementary Figures 2A, B).

TIM3 and LAG3, representative PD-L1 bypass immune checkpoints, were identified with expression levels comparable in SCCCs and ACCs (Supplementary Figure 1). TIM3, other than LAG3, displayed positive correlations with ACC and SCCC areas in tumorous, stromal, and total regions, influenced by an anomalous value from one patient (Supplementary Figures 2C, D).

**Enhanced regulatory T cell and impaired natural killer cell infiltration in squamous cell carcinoma components indicate immunosuppressive phenotype**

We compared proportions of CD3+, CD4+, and CD8+ T cells, CD57+ natural killer (NK) cells, CD4+ FOXP3+ regulatory T cells (T\(_{reg}\)), and CD68+ CD163+ M2 tumor-associated macrophages (TAMs) between paired ACC and SCCC samples, respectively. In the total region, more T\(_{reg}\) (median proportion 0.63% vs. 0.58%, \( p = 0.029 \)) and fewer NK cells (0.27% vs. 0.71%, \( p = 0.049 \)) were enriched in SCCCs versus ACCs (Figure 3A), as subsequently evidenced by MIF results (Figure 3B). Consistently, these trends were detectable in tumorous and stromal regions (Supplementary Figure 3).

However, CD3+, CD4+, and CD8+ T cell proportions were comparable in SCCCs versus ACCs, either in the total region (Figure 3C) or tumorous and stromal regions (Supplementary Figures 3A, B).
M2 TAMs showed a similar trend between SCCC and ACC (Figure 3C and Supplementary Figure 3). Therefore, intratumoral heterogeneity of immune cell infiltration is present in lung ASC.

Squamous cell carcinoma component reveals lower T-cell receptor diversity and higher T-cell receptor clonality than adenocarcinoma component

We assessed the TCR repertoire diversity using TCRβ CDR3 sequencing and found that the TCR diversity in SCCCs was significantly lower than that in ACCs (median value 5.081 vs. 5.526, \( p = 0.029 \)). The TCR clonality in SCCCs was higher than that achieved in ACCs (0.305 vs. 0.272, \( p = 0.041 \)) (Figure 4A). Shannon’s index, as well as clonality, was proportional positively in ACC and SCCC. (\( p < 0.001 \) and \( p = 0.010 \)) (Supplementary Figures 2K, L). These results suggested that the T cell diversity is still limited in SCCCs, together with boosted oligoclonal T-cell expansion, although the amount of CD3+ total T cells remains constant between the two types of pathological components.

Furthermore, we compared the TCR repertoire in ACCs versus stage-matched LUADs (\( n = 60 \)), and in SCCCs versus stage-matched LUSC (\( n = 60 \)), which were sequenced using the same platform and documented in Geneplus-Beijing. Still, SCCCs displayed lower TCR diversity and higher clonality than LUSC (both \( p < 0.001 \)), and similar trends were found in ACCs versus LUAD (both \( p < 0.001 \)) (Figures 4B, C). These findings demonstrated intratumoral heterogeneity of TCR repertoire between ACCs and SCCCs.
Higher tumor mutation burden and intratumoral heterogeneity of immunogenicity in lung adenosquamous carcinoma

We sequenced the genomes of 28 pairs of ACCs and SCCCs to a median depth of 515×. The median TMB in SCCCs was 7.2 mutations/Mb (range 4 to 21.6), higher than that in ACCs (6.5 mutations/Mb, 1.4 to 14.4, \( p = 0.007 \)) (Figure 4D), indicating the component heterogeneity of TMB within lung ASC resulted from the branch evolution between ACCs and SCCCs. The TMBs of ACCs and SCCCs were modestly proportional (\( p = 0.002 \)) (Supplementary Figure 2), influenced by component-shared mutations originated from the same genetic clone.

We next compared TMBs in the two pathological subtypes of lung ASC with those in pure, stage-matched LUADs (\( n = 170 \)) and LUSCs (\( n = 62 \)) (Figure 4E) obtained from Geneplus-Beijing. The median TMB in ACC was comparable with that in LUAD (4.3 mutations/Mb, 1.4 to 44.6, \( p = 0.620 \)), whereas the SCCC TMB was lower than the archival LUSC (10.1 mutations/Mb, 1.4 to 27.4, \( p = 0.030 \)). We further evaluated the median ASC TMB, which was calculated based on integration of non-synonymous somatic mutation (removing duplicates) data from ACC and SCCC samples. Lung ASCs showed a median TMB of
7.9 mutations/Mb (range 1.4 to 27.4), statistically higher than that in pure LUAD \((p = 0.007)\) and close to that in LUSC \((p = 0.300)\).

**Real-world outcome analysis of immune checkpoint inhibitor efficacy in lung adenosquamous carcinoma patients**

Efficacy data from patients treated with anti–PD-1 agents (single or combined with chemotherapy agents) from 11 centers were retrospectively analyzed (Tables 1, 2). Eighteen (39%) patients had complete PD-L1 expression information, and none of the patients had TMB records. Four EGFR-mutant patients were included.

Overall, 100% of patients underwent response evaluation per RECIST criterion. The proportions of patients achieving CR as best response, PR, SD, and PD were 0%, 28%, 43%, and 28%, respectively. These patients showed a median PFS of 6.0 months (95% CI 4.3–7.7 months) and OS of 24.7 months (95% CI 7.2–42.2 months) (Figure 5A). Twenty patients (43%) were treated with mono-ICIs, and 26 (57%) received ICIs plus standard chemotherapy. In the mono-ICI subgroup, patients achieved an ORR of 30% (CR, \(n = 0\) and PR, \(n = 6\)) and a DCR of 65% (PR/SD, \(n = 13\)) with median PFS and OS of 6.0 (95% CI 0.0–15.3) and 24.7 (95% CI 9.6–39.8) months (Figure 5B), compared with a comparable ORR of 27% (PR, \(n = 7\)) and a higher DCR of 77% (PR/SD, \(n = 20\)) in chemo-ICI patients, with median PFS of 6.0 (95% CI 3.7–8.3) months. However, during the median follow-up of 12.2 months, OS was not evaluated due to the special endpoint result—only six patients were deceased (Figure 5C).

Among four EGFR-mutant patients, two of them treated with mono-ICIs both achieved PD within 1 month; another two patients treated with chemo-ICIs were controlled, with 5-month PFS and 18-month OS. Among seven PD-L1-positive patients treated with mono-ICIs, four achieved PR, two achieved SD, and one achieved PD. Their median PFS was 6.8 (95% CI 2.4–11.2) months, and OS was unevaluable. Among another seven PD-L1-positive patients treated with chemo-ICIs, two achieved PR, three achieved SD, and two achieved PD, with median PFS and OS of 9.8 (95% CI 4.8–14.8) and less than 13.1 (95% CI 0–50.3) months.

**Discussion**

Lung ASC patients are still refractory to antitumor treatment, particularly those with no actionable mutations. In this study, we ascertain that the TIME in lung ASC is characterized by immune-excluded or immune-desert phenotype and shows intratumoral heterogeneity regarding immune cell infiltration, immune checkpoint expression, TMB, and TCR repertoire between ACCs and SCCCs. For far too long, previous studies of immunotherapy efficacy in lung ASC have never reported a larger real-world cohort than our analysis, which shows a moderately satisfactory response.

Recently, with a large gene panel and whole-exome sequencing, shared mutations in ACCs and SCCCs have been

| TABLE 1 Demographic and disease characteristics of real-world lung ASC patients. |
|-------------------------------|----------------|----------------|
| Characteristics               | Total (\(n=46\)) | Mono-immunotherapy (\(n=20\)) | Chemoimmunotherapy (\(n=26\)) |
| Age                           | 60.5 (33-82)    | 60.5 (33-82)    | 60.5 (43-78) |
| Age <60 yr, no. (%)           | 21 (46)         | 9 (20)          | 12 (26%)     |
| Sex                           |                |                |               |
| Male, no. (%)                 | 31 (67)         | 13 (65)         | 18 (69)      |
| Female, no. (%)               | 15 (33)         | 7 (35)          | 8 (31)       |
| Driver gene status            |                |                |               |
| EGFR, no. (%)                 | 4 (9)           | 2 (10)          | 2 (8)        |
| ALK fusion, no. (%)           | 1 (2)           | 0 (0)           | 1 (4)        |
| RET fusion, no. (%)           | 1 (2)           | 0 (0)           | 1 (4)        |
| KRAS, no. (%)                 | 3 (7)           | 2 (10)          | 1 (4)        |
| MET 14 skipping, no. (%)      | 1 (2)           | 0 (0)           | 1 (4)        |
| Wild type, no. (%)            | 18 (39)         | 7 (35)          | 11 (42)      |
| Unknown, no. (%)              | 18 (39)         | 7 (35)          | 11 (42)      |
| Treatment line                |                |                |               |
| First, no. (%)                | 17 (37)         | 6 (30)          | 11 (42)      |
| Second, no. (%)               | 14 (30)         | 9 (45)          | 5 (19)       |
| ≥Third, no. (%)               | 15 (33)         | 5 (25)          | 10 (38)      |
| Patient ID | Center | Sex | Age (yr) | Driver gene status | PD-L1 (TPS) | Treatment | Line | RECIST | PFS (months) | PFS status | OS (months) | OS status |
|------------|--------|-----|----------|--------------------|-------------|-----------|------|--------|--------------|------------|-------------|-----------|
| rASC-01    | Center 1 | Male | 67       | Wild type          | <1%         | Immunotherapy + chemotherapy | 1    | SD     | 3.0          | 0          | 4.0         | 0         |
| rASC-02    | Center 1 | Male | 62       | Wild type          | NA          | Immunotherapy + chemotherapy | ≥3   | PR     | 24.0         | 1          | 25.0        | 0         |
| rASC-03    | Center 2 | Male | 64       | EGFR exon 19 deletion | <1%         | Immunotherapy + chemotherapy | ≥3   | SD     | 5.4          | 1          | 18.4        | 0         |
| rASC-04    | Center 2 | Male | 61       | Wild type          | 1%          | Immunotherapy + chemotherapy | 1    | PD     | 1.6          | 1          | 13.4        | 1         |
| rASC-05    | Center 2 | Female | 61 | MET exon 14 skipping | 5%          | Immunotherapy + chemotherapy | ≥3   | PR     | 5.3          | 1          | 24.7        | 1         |
| rASC-06    | Center 2 | Male | 61       | Wild type          | 40%         | Immunotherapy + chemotherapy | 1    | SD     | 11.5         | 0          | 11.5        | 0         |
| rASC-07    | Center 2 | Male | 74       | Wild type          | 20%         | Immunotherapy + chemotherapy | 2    | PR     | 15.6         | 0          | 15.6        | 0         |
| rASC-08    | Center 3 | Male | 77       | RET fusion         | NA          | Immunotherapy + chemotherapy | ≥3   | PD     | 1.3          | 1          | 10.7        | 1         |
| rASC-09    | Center 3 | Male | 64       | Wild type          | 2%          | Immunotherapy + chemotherapy | 2    | PD     | 2.5          | 1          | 2.6         | 0         |
| rASC-10    | Center 4 | Male | 63       | NA                 | 15%         | Immunotherapy + chemotherapy | 1    | SD     | 20.9         | 0          | 20.9        | 0         |
| rASC-11    | Center 4 | Male | 68       | KRAS               | NA          | Immunotherapy + chemotherapy | 2    | PD     | 0.7          | 1          | 16.4        | 1         |
| rASC-12    | Center 4 | Female | 47 | Wild type          | <1%         | Immunotherapy + chemotherapy | 1    | PD     | 6.6          | 1          | 6.6         | 0         |
| rASC-13    | Center 4 | Male | 51       | Wild type          | NA          | Immunotherapy + chemotherapy | 2    | PR     | 1.4          | 1          | 1.4         | 1         |
| rASC-14    | Center 4 | Male | 43       | Wild type          | NA          | Immunotherapy + chemotherapy | 2    | SD     | 15.6         | 1          | 52.3        | 0         |
| rASC-15    | Center 4 | Male | 54       | Wild type          | NA          | Immunotherapy + chemotherapy | 1    | SD     | 6.0          | 1          | 11.9        | 1         |
| rASC-16    | Center 4 | Female | 78 | Wild type          | NA          | Immunotherapy + chemotherapy | 2    | SD     | 24.0         | 1          | 44.9        | 0         |
| rASC-17    | Center 4 | Male | 60       | Wild type          | NA          | Immunotherapy + chemotherapy | ≥3   | SD     | 7.9          | 1          | 22.7        | 0         |
| rASC-18    | Center 4 | Male | 57       | KRAS               | <1%         | Immunotherapy + chemotherapy | 2    | SD     | 30.2         | 0          | 30.2        | 0         |
| rASC-19    | Center 4 | Male | 68       | Wild type          | NA          | Immunotherapy + chemotherapy | 1    | SD     | 25.6         | 1          | 33.6        | 0         |
| rASC-20    | Center 5 | Male | 54       | NA                 | NA          | Immunotherapy + chemotherapy | 2    | PD     | 2.6          | 1          | 6.0         | 1         |
| rASC-21    | Center 5 | Female | 50 | NA                | NA          | Immunotherapy + chemotherapy | ≥3   | SD     | 1.9          | 1          | 12.7        | 0         |
| rASC-22    | Center 5 | Female | 60 | NA                | NA          | Immunotherapy + chemotherapy | 2    | PD     | 0.7          | 1          | 6.4         | 0         |
| rASC-23    | Center 5 | Female | 43 | NA                | NA          | Immunotherapy + chemotherapy | 1    | SD     | 5.1          | 1          | 8.6         | 0         |
| rASC-24    | Center 5 | Male | 55       | NA                 | NA          | Immunotherapy + chemotherapy | 2    | PD     | 1.3          | 1          | 15.4        | 1         |
| rASC-25    | Center 5 | Male | 82       | NA                 | NA          | Immunotherapy + chemotherapy | 1    | PD     | 0.7          | 1          | 0.7         | 0         |
| rASC-26    | Center 6 | Male | 53       | NA                 | ≥50%        | Immunotherapy + chemotherapy | ≥3   | SD     | 8.4          | 0          | 14.5        | 0         |
| rASC-27    | Center 6 | Female | 50 | NA                | NA          | Immunotherapy + chemotherapy | ≥3   | PR     | 7.0          | 1          | 7.7         | 1         |
| rASC-28    | Center 6 | Female | 66 | EGFR L858R +T790M | NA          | Immunotherapy + chemotherapy | ≥3   | PR     | 18.8         | 0          | 26.1        | 0         |
| rASC-29    | Center 7 | Male | 59       | NA                 | NA          | Immunotherapy + chemotherapy | 2    | SD     | 6.4          | 0          | 6.4         | 0         |
| rASC-30    | Center 7 | Male | 48       | NA                 | NA          | Immunotherapy + chemotherapy | ≥3   | SD     | 3.3          | 1          | 18.7        | 0         |
| rASC-31    | Center 8 | Female | 68 | NA                | NA          | Immunotherapy + chemotherapy | 2    | PR     | 16.0         | 1          | 16.3        | 1         |
| rASC-32    | Center 8 | Female | 61 | NA                | NA          | Immunotherapy + chemotherapy | 1    | PR     | 3.5          | 1          | 15.1        | 1         |

(Continued)
shown to result in the monoclonal origin of lung ASC (11, 21).

These shared alterations are trunks in the phylogenetic tree and are, particularly actionable mutations (e.g., EGFR and KRAS mutations), frequently identified in driver genes, underlying the proposal of simultaneous treatment for pathologically biphasic components. EGFR mutations have been proven to have strong associations with immunotherapy resistance in NSCLC (22). MDM2 amplification, considered a factor leading to hyperprogression during immunotherapy in NSCLC (23), is also frequently detected in lung ASC (11). These high-frequency resistance-related genomic factors should therefore be elicited during the management of lung ASC.

The immunophenotypes that we detected may confer characteristics of “altered” and “cold” tumors in lung ASC, a new approach for tumor classification (hot, altered, and cold immune tumors) proposed by Camus et al. for primary colorectal cancer in 2009 (24). These high-frequency resistance-related genomic factors should therefore be elicited during the management of lung ASC.

The immunophenotypes that we detected may confer characteristics of “altered” and “cold” tumors in lung ASC, a new approach for tumor classification (hot, altered, and cold immune tumors) proposed by Camus et al. for primary colorectal cancer in 2009 (24). This new classification method is based on TIL density in tumors and stromal regions, and it suggests that lung ASC is not regularly hot tumors as the total amount of TILs in the tumorous region was lower than 10%, and that lung ASC had relatively higher immunogenicity as it had a relatively higher TMB than LUAD but was comparable with that in LUSC. These characteristics indicate that the use of immunotherapy to improve the outcome is challenging, although higher TMB has been utilized as a predictor for monitoring ICI efficacy or adjustment of the initial strategy (26). Our finding that lung ASC patients receiving mono-immunotherapy and chemoimmunotherapy had an ORR of 28% and PFS of 6.0 months marks a benefit of these patients from ICI-based therapy, although ASC has been categorized into altered and cold tumors.

Molecular and cellular heterogeneity between ACCs and SCCCs has been demonstrated in this study, which can be associated with branch evolution and selection. SCCCs had higher PD-L1 expression, TMB, TCR clonality, and Tregs.

### Table 2

| Patient ID | Center | Sex | Age (yr) | Driver gene status | PD-L1 (TPS) | Treatment | Line RECIST | PFS (months) | PFS status | OS (months) | OS status |
|------------|--------|-----|----------|--------------------|-------------|-----------|-------------|--------------|------------|-------------|------------|
| rASC-33    | Center 8 | Male | 54       | NA                 | NA          | Immunotherapy | ≥3 SD       | 2.0         | 0           | 2.0         | 0          |
| rASC-34    | Center 8 | Female | 51       | NA                 | NA          | Immunotherapy | 1 PR        | 8.0         | 1           | 10.7        | 0          |
| rASC-35    | Center 8 | Male | 63       | NA                 | NA          | Immunotherapy | 2 SD        | 11.2        | 1           | 11.2        | 0          |
| rASC-36    | Center 9 | Male | 55       | Wild type          | NA          | Immunotherapy | ≥3 PD       | 1.5         | 1           | 1.5         | 0          |
| rASC-37    | Center 9 | Female | 68       | EGFR L858R +T790M  | NA          | Immunotherapy | 2 PD        | 0.7         | 1           | 1.5         | 1          |
| rASC-38    | Center 9 | Male | 52       | NA                 | NA          | Immunotherapy | 1 SD        | 5.0         | 1           | 6.7         | 0          |
| rASC-39    | Center 9 | Female | 61       | ALK fusion         | NA          | Immunotherapy | ≥3 PD       | 1.5         | 1           | 1.5         | 1          |
| rASC-40    | Center 10 | Female | 53       | Wild type          | 90%         | Immunotherapy | 1 PR        | 1.7         | 0           | 5.9         | 0          |
| rASC-41    | Center 10 | Male | 58       | Wild type          | 15%         | Immunotherapy | 1 PR        | 5.1         | 1           | 7.3         | 0          |
| rASC-42    | Center 10 | Male | 65       | NA                 | 70%         | Immunotherapy | 1 PR        | 9.8         | 1           | 36.1        | 1          |
| rASC-43    | Center 10 | Female | 33       | EGFR R831H         | 60%         | Immunotherapy | ≥3 PD       | 0.7         | 1           | 0.7         | 0          |
| rASC-44    | Center 11 | Male | 62       | KRAS               | 60%         | Immunotherapy | 1 PR        | 15.7        | 0           | 16.5        | 0          |
| rASC-45    | Center 11 | Male | 50       | Wild type          | ≥50%        | Immunotherapy | ≥3 SD       | 6.0         | 1           | 7.1         | 1          |
| rASC-46    | Center 11 | Male | 78       | Wild type          | 20%         | Immunotherapy | 1 SD        | 6.8         | 1           | 7.0         | 0          |
proportions than ACCs. Particularly, PD-L1 was predominantly expressed in SCCCs compared with ACC. Consistently, a recent study also reported that PD-L1 expression discrepancy between the two histological components within lung ASC could be seen on images, although the histological data were not compared (27). PD-L1 expression in squamous cells was also observed in 15 pancreatic ASCs (28). PD-L1 has been identified as an immune checkpoint molecule contributing to immune evasion. Our previous study showed that SCCCs of lung ASCs could be transformed from ACC (11), similar to LUSC transformation from LUAD that has been observed in several cases after EGFR-TKI treatment (29). From these results, it can be hypothesized that the selective PD-L1 expression may encourage SCCC branch evolution through the suppressed regulation of the immune microenvironment. Lung ASC also has a significant association with a poor prognosis (4–6). Immune escape associated with high PD-L1 expression in SCCCs can be partly explained by less inflammatory infiltration to tumor cells in this component. However, we are unable to reveal the genetic mechanism for selective PD-L1 expression and SCCC histogenesis due to incomplete gene panel sequencing information.

The limitations are apparent, including limited sample size and the selected population in which most cases are driver gene-negative in the real-world cohort. This selection bias is associated with sparingly clinical attempts at immunotherapy in EGFR-mutant ASC patients, as EGFR-mutant NSCLC is generally considered to be less responsive to immunotherapy. Unfortunately, we failed to directly analyze the association between TIME and treatment efficacy in the real-world cohort, which is expected to be explored in future prospective studies (30, 31).

Conclusions

Lung ASC features high-frequent EGFR mutations, generally suppressive TIME, and genetic and immunoheterogeneity between ACCs and SCCCs. Lung ASC patients without EGFR mutations have a moderate response to ICI-based immunotherapy.

Data availability statement

The data presented in the study are deposited in the NCBI Sequence Read Archive, accession number PRJNA865459.

Ethics statement

The studies involving human participants were reviewed and approved by Fujian Cancer Hospital Ethics Committee. The
patients/participants provided their written informed consent to participate in this study.

Author contributions

GL, BZ, and CL conceived the study idea and designed the study. CL and XBZ prepared research materials. HJW, JH, LW, ZJW, HG, FW, WZZ, ZZC, QC, JZ, LFZ, KJ, QM, YQX, SWW, HBW, SSY, YJL, and CH collected clinical data. WJX and WFZ performed pathology. PSL, XLZ, and QL performed guidance to them for accurate bioinformatics and statistical analyses. GL was accountable for all aspects of the study. CL, XBZ, PSL drafted the manuscript or revised it critically for important intellectual content. All the authors reviewed the paper and approved the final manuscript.

Funding

This study was supported by the China Southwest Oncology Group (CSWOG), a national collaborative clinical research group of 97 member hospitals, National Natural Science Foundation of China (82072565), Beijing Xisike Clinical Oncology Research Foundation (Y-2019AZZD-0386), Fujian Provincial Health and Family Research Talent Training Program[2018- CX-12], Fujian Provincial Science and Technology Department guided projects (2020Y9038), Fujian Provincial Health Systemic Innovation Project (2020CXA010), Fujian Provincial Health Commission (2020QNA014), Fujian Provincial Natural Science Foundation (2020J01120), Fujian Provincial Natural Science Foundation (2021J01432), Youth Program of National Natural Science Foundation of China (82102991), Fujian Provincial Natural Science Foundation (2021J05084), and Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (2020Y2012). Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis.

Conflict of interest

Authors PL, QL, XX and XY were employed by the company Geneplus-Beijing.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.944812/full#supplementary-material

References

1. Li C, Lu H. Adenosquamous carcinoma of the lung. OncoTargets Ther (2018) 11:4829–35. doi: 10.2147/OTT.S164574
2. Rao N. Adenosquamous carcinoma. Semin Diagn Pathol (2014) 31:271–7. doi: 10.1053/j.semdp.2014.06.004
3. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol (2015) 10:1240–2. doi: 10.1097/JTO.0000000000000663
4. Mordant P, Grand B, Cazes A, Foucault C, Dujon A, Le Pimpec-Barthes F, et al. Adenosquamous carcinoma of the lung: Surgical management, pathologic characteristics, and prognostic implications. Ann Thorac Surg (2013) 95:1189–95. doi: 10.1016/j.athoracsur.2012.12.037
5. Maeda H, Matsumura A, Kawabata T, Suito T, Kawashima O, Watanabe T, et al. Adenosquamous carcinoma of the lung: Surgical results as compared with squamous cell and adenocarcinoma cases. Eur J Cardio-Thoracic Surg (2012) 41:357–61. doi: 10.1016/j.ejcts.2011.05.050
6. Filosso PL, Ruffini E, Asioli S, Giobbe R, Macri L, Bruna MC, et al. Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. Lung Cancer (2011) 74:25–9. doi: 10.1016/j.lungcan.2011.01.030
7. Shi C, Cheng H, Wang A, Mansukhani MM, Powell CA, Halmos B, et al. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Modern Pathol (2013) 26:239–46. doi: 10.1038/modpathol.2012.158
8. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer (2007) 55:129–30. doi: 10.1016/j.lungcan.2006.09.003
9. Kang SM, Kang HJ, Shin HJ, Kim H, Shin DH, Kim SK, et al. Identical epidermal growth factor receptor mutations in adenosquamous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer (2007) 109:581–7. doi: 10.1002/cncr.22413
10. Tochigi N, Dacci S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of the lung: A microdissection study of KRAS and EGFR mutational and amplification status in a Western patient population. Am J Clin Pathol (2011) 135:783–9. doi: 10.1309/AJCPI9BZQAOGYFLF
11. Lin G, Li C, Li PS, Fang WZ, Xu HP, Gong YH, et al. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. Ann Oncol (2020) 31:517–24. doi: 10.1016/j.annonc.2020.01.014
12. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med (2018) 24:541–50. doi: 10.1038/s41591-018-0014-x
13. Shi X, Wu S, Sun J, Liu Y, Zeng X, Liang Z. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep (2017) 7:46209. doi: 10.1038/s41598-017-10500-w
14. Trosano G, Rubini C, Togni L, Caponio VCA, Zhurakivka K, Santarelli A, et al. The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis. Cancer Med (2020) 9:8333–44. doi: 10.1002/cam4.3440

15. Salgado R, Denkert C, Demaria S, Sirtaine N, Fuchs C, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol (2015) 26:259–71. doi: 10.1093/annonc/mdu50

16. Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun (2018) 9:5361. doi: 10.1038/s41467-018-07767-w

17. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: Software for comprehensive adaptive immunity profiling. Nat Methods (2015) 12:380–1. doi: 10.1038/nmeth.3364

18. Tumeh PC, Harvieux CL, Yearely JH, Shintaku IP, Taylor EL, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515:566–71. doi: 10.1038/nature13954

19. Gorris MAJ, Hallovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, et al. Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment. J Immunol (2018) 200:347–54. doi: 10.4049/jimmunol.1701262

20. Gettinger S, Hellmann MD, Chow LQM, Borchgrevin K, Antonia S, Brahmer JR, et al. Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J Thorac Oncol (2018) 13:1363–72. doi: 10.1016/j.jtho.2018.05.015

21. Krause A, Roma L, Lorber T, Habicht J, Lardinois D, De Filippo MR, et al. Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. Lung Cancer (2020) 150:132–8. doi: 10.1016/j.lungcan.2020.10.013

22. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meeting (2019) 39:147–64. doi: 10.1200/EKBK.240837

23. Hou H, Sun D, Zhang X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int (2019) 19:216. doi: 10.1186/s12935-019-0937-4

24. Camus M, Tosolini M, Milecnik B, Pagès F, Kirilovsky A, Berger A, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 69:2685–93. doi: 10.1158/0008-5472.CAN-08-2654

25. Pagès F, Milecnik B, Marlot F, Bindea G, Ou FS, Bisfulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet (London Englangd) (2018) 393:2128–39. doi: 10.1016/S0140-6736(18)30789-X

26. Chan TA, Yachoo M, Jaffe E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol (2019) 30:44–56. doi: 10.1093/annonc/mdy495

27. Liu Y, Dong Z, Jiang T, Hou L, Wu F, Gao G, et al. Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenocarcinoma. Clin Lung Cancer (2019) 19:e421–30. doi: 10.1016/j.cllc.2018.02.008

28. Tanigawa M, Naito Y, Akiba J, Kawahara A, Okabe Y, Ishida Y, et al. PD-L1 expression in pancreatic adenocarcinoma: PD-L1 expression is limited to the squamous component. Pathol Res Pract (2018) 214:2069–74. doi: 10.1016/j.prp.2018.10.006

29. Izumi H, Yamasaki A, Ueda Y, Sumikawa T, Maeta H, Nakamoto S, et al. Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: A case report and literature review. Clin Lung Cancer (2018) 19:e63–6. doi: 10.1016/j.cllc.2017.10.005

30. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin Cancer Res (2016) 22:4585–93. doi: 10.1158/1078-0432.CCR-15-3101

31. Lee CK, Man J, Lord S, Cooper W, Links M, Gębski V, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis. JAMA Oncol (2018) 4:210–6. doi: 10.1001/jamaoncol.2017.4427

COPYRIGHT © 2022 Li, Zheng, Li, Wang, Hu, Wu, Wang, Guo, Wu, Zhong, Zhou, Chu, Zhao, Zheng, Xiao, Zhu, Zhang, Li, Jiang, Miao, Wu, Xu, Wu, Wang, Yang, Li, Xia, Yi, Huang, Zhu and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.